This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

10X Genomics says Bio-Rad can't avoid US antitrust counterclaims

( July 19, 2021, 22:31 GMT | Official Statement) -- MLex Summary: 10X Genomics told a US judge that it has presented ample evidence of Bio-Rad Laboratories’ illegal monopolization of multiple markets relating to genetic analysis, and 10X's claims shouldn't be resolved by summary judgment. 10X filed an opposition to Bio-Rad’s motion, saying when Bio-Rad bought RainDance, it consolidated two patent portfolios knowing it would eliminate licensing competition between Bio-Rad and RainDance, force licensees who could have chosen RainDance to come to Bio-Rad, and allow Bio-Rad to raise license prices or foreclose its competitors altogether.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections